BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

INX-189: Phase Ib ongoing

Inhibitex said it plans to expand a double-blind, placebo-controlled, U.S. Phase Ib trial in treatment-naïve patients with chronic HCV genotype 1 infection trial to include 3 additional cohorts evaluating once-daily 200 mg INX-189 plus Copegus ribavirin, once-daily 300 mg INX-189 as...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >